Phase 1b clinical trial of SYX-5219 in adults with moderate to severe atopic dermatitis completes enrollment ahead of ...
Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, today announced enrollment and dosing has ...
For millennia, thick, healthy hair has symbolized both masculine virility and feminine appeal. So when hair thins or ...
Researchers at the University of Surrey have identified a protein that acts as a control switch, preventing Mycobacterium ...
The best creatine supplements boost your exercise performance and help you build stronger muscles faster, from Myprotein, ...
A protein that acts as a 'control switch,' preventing Mycobacterium tuberculosis from accessing the energy sources it needs ...
Although abolishing the Crabtree effect in Saccharomyces cerevisiae through a pyruvate dehydrogenase bypass eliminates carbon loss through ethanol overflow metabolism, it compromises growth rates.
To comprehensively evaluate objective measures of hemolysis alongside other clinically relevant outcomes in sickle cell disease, the double-blind period of RISE UP included two primary endpoints – ...
Agios' shares rose 35% in six months as Aqvesme gains traction, mitapivat expands globally and new ITP rights add to its rare blood disease push.
Washington, District of Columbia, United States, June 14, 2026 (GLOBE NEWSWIRE) -- Washington, DC – More than 100 prominent organizations from ...
Learn how a Phase 3 trial shows mitapivat significantly improves anaemia and haemolysis in sickle cell disease.
Agios Pharmaceuticals, Inc. a présenté les résultats détaillés de la période en double aveugle de 52 semaines de l'essai mondial de phase 3 RISE UP évaluant le mitapivat, un activateur oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results